Last Updated on August 11, 2022 by GlobeNewsWire
???????????, Aug. 12, 2022 (GLOBE NEWSWIRE) —
??mavacamten??III????????;????2023???????????????mavacamten???????(NDA)??????????????????(NDA)2022?????????????????????2022??????????3.494???,?????????2024????
????(????:LIAN),????????????????????????????????,????????2022?6?30????????????????????
“??????????????????????,???????????????????????????????????????”????????????????,”??????????,????????????????????????????????????????????????????????????,???????????????????????????????,???mavacamten?EXPLORER-CN III????????,????mavacamten????????????????????????mavacamten?????????????(oHCM)???,?????????????oHCM?????????,????????2023?????EXPLORER-CN??????????,EXPLORER-CN???????????????????,??????????????????,???????????????????????????????????????????????,????????????????????????????????????????????????????????,??????”
?????????????:
Mavacamten???????????,??III?????????,?????????????
2022?5?,????????????????mavacamten???????,?????????????????II-III??????????????(oHCM)??????????????????????(FDA)??mavacamten????2022?8?,mavacamten??????oHCM???EXPLORER-CN III??????????????
?????????????????,???????????
2022?7?,?????????????????????????????????,?????????????????-2(FGFR2)?????????????????????????????????????????????FDA????????????
??????ReViral???????
2022?6?,?????????????????ReViral????sisunatovir?????????????????????????????????????????sisunatovir??????????
??LYR-210???????
??????????Lyra??????III???,????2023????????????????????,???????????????III???,???????????
??????Tarsus??TP-03??????????????
2022?8?,??????????Tarsus???TP-03????????(MGD)????IIa??????
??????Landos Biopharma??NX-13????
2022?8?,Landos??NX-13 Ib??????????,???NX-13????????????,Landos??????II?????,??NX-13???????????????????????
????????,???????????
??????????????2024??????????
2022??2023??????????:
Mavacamten
LianBio????2023?????mavacamten??????????oHCM???EXPLORER-CN III?????????
TP-03
????????2022??????TP-03?????????????III??????????????????TP-03?????????
NBTXR3
???????2022?????Nanobiotix?NANORAY-312??III?????????????????,???????????????????????????????????????NBTXR3?????????????????????????
??????
?????????????IIa?????????????,???????????FGFR2??????????????????????????,??????FGFR????????????????????2022?????Helsinn????????????????III?????PROOF-301????????????,??????FGFR2????????????????
BBP-398
???????2022???????BBP-398?I?????????,???????????????????2023??????BBP-398?EGFR??????????????I??????
2022?????????:
????2022??????????2,860???,2021???????9,300??????2022?6?30??????????4,090???,??2021?6?30??????1.464???????????????????????2021?????????,?????2022???????????????????????????????????
?????????2022???????????????1,460???,2021??????650???;??2022?6?30???????????????3,060???,??2021?6?30??????1,360?????????????????????????????????????(????????)???,?????????????????
???2022?????????4,240???,2021?????????1.004???;??2022?6?30?????????7,010???,??2021?6?30?????????1.62????
??????2022?6?30?,???????????????????3.494???,??2021?12?31???????4.032??????????????????????????????????????2024??????????
??????????(LianBio)???????????,??????????????????????????????????????,???????????????????????,????????????????????????????????????????????????????,???????????????,???????????????????????????????,???????:www.lianbio.com
??????????????????????????????????????????,???????????????????????”??”?”??”?”??””??”?”??”?”??”?”??”?????????????,???????????????????????????????????????,????????????????:???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????,??????????????????????????????????????????????????????,????????????????????????,??:???????????????????????,??????????????????;???????????????????????????????,??????????,??????????????????;??????????????????????????;????????????????;??????;?????????????,???LianBio??????????(SEC)????????????????,????2021?12?31??10-K?????????????????????????????????????????,LianBio???????????????????,??????????????????????????????????????????????
??????:Elizabeth Anderson, VP Communications and Investor RelationsE: elizabeth.anderson@lianbio.com T: (646) 655-8390
?????:Katherine Smith, Evoke CanaleE: katherine.smith@evokegroup.com T: (619) 849-5378
LianBioConsolidated Balance Sheets(In thousands, except share and per share amounts) (Unaudited)
June 30,2022 December 31,2021Assets Current assets: Cash and cash equivalents$134,334 $228,182 Marketable securities 194,965 155,067 Prepaid expenses and other current assets 7,141 10,354 Other receivable 7,264 6,044 Total current assets 343,704 399,647 Restricted cash, non-current 20,075 20,000 Property and equipment, net 2,992 1,882 Operating lease right-of-use assets 5,003 4,763 Other non-current assets 39 51 Total assets$371,813 $426,343 Liabilities and Shareholders’ Equity Current liabilities: Accounts payable$1,234 $3,231 Accrued expenses 17,972 9,976 Current portion of operating lease liabilities 1,803 1,125 Other current liabilities 738 760 Total current liabilities 21,747 15,092 Operating lease liabilities 3,660 3,709 Other liabilities 208 206 Nonrefundable research deposit 20,000 20,000 Total liabilities$45,615 $39,007 Commitments and contingencies (Note 8) Ordinary shares, $0.000017100448 par value. Authorized 2,923,900,005 shares as of June 30, 2022; 108,353,831 shares issued and outstanding at June 30, 2022; Authorized 2,923,900,005 shares as of December 31, 2021; 107,275,458 shares issued and outstanding at December 31, 2021 2 2 Additional paid-in capital 724,176 713,269 Accumulated other comprehensive (loss) income (1,402) 526 Accumulated deficit (430,352) (360,235)Total LianBio shareholders’ equity 292,424 353,562 Non-controlling interest 33,774 33,774 Total shareholders’ equity 326,198 387,336 Total liabilities and shareholders’ equity$371,813 $426,343
LianBioStatements of Operations and Comprehensive Loss(In thousands, except share and per share amounts) (Unaudited)
Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021Operating expenses: Research and development$28,591 $93,030 $40,920 $146,383 General and administrative 14,551 6,461 30,639 13,607 Total operating expenses 43,142 99,491 71,559 159,990 Loss from operations (43,142) (99,491) (71,559) (159,990)Other income (expense): Interest income, net 553 106 833 139 Other income (expense), net 203 (68) 620 (192)Net loss before income taxes (42,386) (99,453) (70,106) (160,043)Income taxes 5 975 11 1,950 Net loss (42,391) (100,428) (70,117) (161,993)Other comprehensive (loss) income: Foreign currency translation (loss) income, net of tax (421) 122 (814) 130 Unrealized loss on marketable securities, net of tax (291) — (1,114) — Comprehensive loss$(43,103) $(100,306) $(72,045) $(161,863)Net loss per share attributable to ordinary shareholders, basic and diluted$(0.39) $(4.90) $(0.65) $(7.91)Weighted-average shares outstanding used in computing net loss per share attributable to ordinary shareholders, basic and diluted 107,922,501 20,477,338 107,600,767 20,477,338
